Our Therapeutic Areas
Gilead is committed to advancing care for people around the world, by bringing forward medicines in areas of unmet medical need. We do this through internal research and development, as well as through collaborations with academic and industry partners.
Since 1987, Gilead has delivered more than 25 innovative medicines, helping to improve treatment for people living with diseases such as HIV, viral hepatitis, cancer and other conditions.
Gilead has transformed care for people living with HIV, pioneering inventions that were once thought impossible: The first single-tablet regimen and the first medicine licensed for pre-exposure prevention of HIV transmission. Our work in HIV continues to span the full continuum of HIV care – from prevention to treatment to working toward the ultimate goal: a cure. Beyond the science, we partner with our allies to help address the root causes driving the HIV epidemic, and are working to ensure that people living with HIV, and those at risk of infection, have access to our medicines.
Hepatitis C and B
With the same tenacity, innovation and focus that drove our work in HIV, we delivered four curative treatments for chronic hepatitis C virus in less than four years. Today, more than 4 million people have received our therapies and we continue to reach more people around the world. We have also been on the front lines of transforming care for people with chronic hepatitis B virus for 20 years and are actively pursuing multiple pathways toward a possible cure.
Treating the COVID-19 Public Health Crisis
We are committed to treating the pandemic, applying our deep antiviral knowledge and relentless innovation. We are studying ways to enhance the disruption of viral replication to advance novel treatments to help more people. Our efforts include both expanding our internal research programs and working with the broader scientific community.
Our Kite operating company is a leader in cell therapy. Kite’s development program is robust, with numerous ongoing and completed pivotal studies, as well as one of the largest cell therapy research programs.
We are also seeking to advance oncology programmes outside of cell therapy, primarily focusing on investigational compounds that leverage our understanding of the immune system and have the potential to be first-in-class medicines.
We work closely with patient groups, healthcare professionals, the NHS and industry to build relationships that will help bring lasting improvements to people’s health.